stockrow
Friday 6 November 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024.
- Revenue
- +67.1%
- EPS
- +15.4%
- Free cash flow
- +73.4%
- Total debt
- +45.9%
Quarter to June 2026, against a year earlier
1.86
0.04
−2.11%
Follow CAPS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.17 | 0.08 | 0.12 | 0.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
0.00 | (9.21) | (2.23) | (8.23) | |
P/B ratio |
0.30 | 0.31 | 0.56 | 0.26 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.58 | 0.57 | 0.61 | 0.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.43) | (6.01) | (6.42) | (7.90) | |
EV/FCF |
(21.07) | (5.85) | (6.25) | (7.46) | |
Quick Ratio |
0.32 | 0.24 | 0.27 | 0.35 | |
Current Ratio |
0.95 | 1.00 | 0.95 | 0.99 | |
Net Debt/EBITDA |
(46.35) | (3.45) | (26.46) | 12.95 | |
Debt/Assets |
32.87% | 45.47% | 48.09% | 46.56% | |
Debt/Equity |
0.71 | 1.88 | 2.31 | 2.05 | |
Asset Turnover |
1.51 | 0.95 | 0.97 | 1.13 | |
Operating CF/Net income |
0.00 | 0.03 | 1.46 | 0.28 | |
Capex/Depreciation |
(0.04) | (0.07) | (0.05) | (0.04) | |
Interest Coverage |
(1.29) | (3.34) | (1.68) | 0.22 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.68% | 38.96% | 35.35% | 25.65% | |
Intangible Assets out of Total Assets |
0.45 | 0.40 | 0.38 | 0.37 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.64) | (4.11) | (2.67) | (4.80) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(607.35%) | (499.13%) | (505.75%) | (1,320.22%) | |
Free Cash Flow Yield |
(16.52%) | (117.16%) | (81.48%) | (118.83%) | |
Revenue per Share |
71.94 | 70.41 | 40.67 | 51.02 | |
Operating CF per Share |
0.00 | (2.37) | (8.98) | (0.93) | |
Capex per Share |
(0.08) | (0.80) | (0.09) | (0.15) | |
Free Cash Flow per Share |
(0.08) | (3.17) | (9.07) | (1.08) | |
Cash per Share |
3.85 | 4.10 | 1.35 | 0.53 | |
Shareholders Equity per Share |
143.08 | 70.28 | 36.12 | 29.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
143.08 | 70.28 | 36.12 | 29.50 | |
Free Cash Flow |
(0.02) | (0.56) | (2.82) | (0.45) | |
Working Capital |
(0.91) | 0.08 | (1.44) | (0.24) | |
Capital Expenditures |
(0.02) | (0.14) | (0.03) | (0.06) | |
Net Current Asset Value |
(12.21) | (15.92) | (16.59) | (15.39) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 3.81 | 5.71 | 7.43 | |
Average Payables |
3.14 | 4.13 | 5.67 | 5.20 | |
Average Inventory |
— | 13.35 | 13.92 | 12.99 | |
Average Assets |
29.59 | 49.30 | 53.00 | 53.28 | |
Average Common Equity |
11.22 | 4.68 | 19.08 | 19.32 |
Columns are period end dates · fundamentals updated 2 Nov 2026